Troy Edward Wilson Kura Oncology, Inc. (KURA) insider trading activity

Troy Edward Wilson is President and CEO of Kura Oncology, Inc.. Currently has a direct ownership of 429,353 shares of KURA, which is worth approximately $4.81 Million. The most recent transaction as insider was on Nov 13, 2025, when has been sold 182,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 429K

73.93% 3M change

76707.33% 12M change

Total Value Held $4.81 Million

TROY EDWARD WILSON Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 13 2025	BUY Grant, award, or other acquisition	-	182,500 Added 29.83%	429,353 Common Stock
Sep 29 2025	SELL Open market or private sale	$327,338 $8.94 p/Share	36,615 Reduced 12.92%	246,853 Common Stock
Sep 27 2025	BUY Grant, award, or other acquisition	-	182,500 Added 39.17%	283,468 Common Stock
Sep 08 2025	BUY Open market or private purchase	$409,999 $8.2 p/Share	50,000 Added 33.12%	100,968 Common Stock
Aug 13 2025	BUY Open market or private purchase	$89,600 $6.64 p/Share	13,494 Added 20.93%	50,968 Common Stock
Aug 12 2025	BUY Open market or private purchase	$213,560 $5.85 p/Share	36,506 Added 49.35%	37,474 Common Stock
Jan 24 2024	SELL Open market or private sale	$1,841,981 $20.23 p/Share	91,052 Reduced 99.39%	559 Common Stock

Jan 24 2024	BUY Exercise of conversion of derivative security	$498,964 $5.48 p/Share	91,052 Added 51.82%	84,666 Common Stock
Dec 07 2023	SELL Bona fide gift	-	2,000 Reduced 78.16%	559 Common Stock
Jun 02 2023	SELL Other acquisition or disposition	-	27,966 Reduced 91.62%	2,559 Common Stock
Aug 19 2022	SELL Other acquisition or disposition	-	11,985 Reduced 28.19%	30,525 Common Stock
Dec 01 2020	BUY Exercise of conversion of derivative security	$72,908 $6.15 p/Share	11,855 Added 22.88%	39,951 Common Stock
Oct 08 2020	SELL Open market or private sale	$1,712,580 $34.0 p/Share	50,370 Reduced 64.19%	28,096 Common Stock
Oct 08 2020	BUY Exercise of conversion of derivative security	$309,776 $6.15 p/Share	50,370 Added 39.1%	78,466 Common Stock
Oct 07 2020	SELL Open market or private sale	$155,924 $34.0 p/Share	4,586 Reduced 14.03%	28,096 Common Stock
Oct 07 2020	BUY Exercise of conversion of derivative security	$28,204 $6.15 p/Share	4,586 Added 12.31%	32,682 Common Stock

Also insider at

RNA

Avidity Biosciences, Inc. Healthcare

Director

PBYI

PUMA BIOTECHNOLOGY, INC. Healthcare

Director

TEW